@article{MTMT:34804716,
	title = {Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment},
	url = {https://m2.mtmt.hu/api/publication/34804716},
	author = {Rouleau, Jean},
	doi = {10.1056/NEJMe2402719},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	unique-id = {34804716},
	issn = {0028-4793},
	abstract = {A number of therapies that have been shown to be effective in patients with chronic heart failure, including beta-blockers, mineralocorticoid receptor antagonists, and renin-angiotensin system inhibitors, have also been shown to be beneficial in patients with evidence of left ventricular systolic dysfunction, pulmonary congestion, or both after an acute myocardial infarction.(1) However, the effectiveness of an agent in patients with chronic heart failure does not necessarily imply that the agent will be effective in patients who have had an acute myocardial infarction. For example, despite the effectiveness of sacubitril-valsartan in decreasing the risk of death from cardiovascular causes or hospitalization . . .},
	year = {2024},
	eissn = {1533-4406}
}

@article{MTMT:34804386,
	title = {HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize?},
	url = {https://m2.mtmt.hu/api/publication/34804386},
	author = {Ballantyne, Christie M. and Nambi, Vijay},
	doi = {10.1056/NEJMe2403036},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	unique-id = {34804386},
	issn = {0028-4793},
	abstract = {The identification of an inverse association between high-density lipoprotein (HDL) cholesterol levels and incident cardiovascular disease events,(1) combined with research on the role of HDL in reverse cholesterol transport, led to the exploration of therapies directed toward increasing HDL cholesterol. However, although therapies such as cholesteryl-ester transfer protein inhibitors increased HDL cholesterol levels, these therapies did not reduce the incidence of cardiovascular disease events.(1,2) Consequently, the focus of HDL therapeutics shifted to attempting to improve the functionality, or quality, of HDL, and efforts to measure and enhance cholesterol efflux capacity and thereby promote reverse cholesterol transport were initiated.(1,2) Although the . . .},
	year = {2024},
	eissn = {1533-4406}
}

@article{MTMT:34801043,
	title = {Empagliflozin after Acute Myocardial Infarction},
	url = {https://m2.mtmt.hu/api/publication/34801043},
	author = {Butler, Javed and Jones, W. Schuyler and Udell, Jacob A. and Anker, Stefan D. and Petrie, Mark C. and Harrington, Josephine and Mattheus, Michaela and Zwiener, Isabella and Amir, Offer and Bahit, M. Cecilia and Bauersachs, Johann and Bayes-Genis, Antoni and Chen, Yundai and Chopra, Vijay K. and Figtree, Gemma and Ge, Junbo and Goodman, Shaun G. and Gotcheva, Nina and Goto, Shinya and Gasior, Tomasz and Jamal, Waheed and Januzzi, James L. and Jeong, Myung Ho and Lopatin, Yuri and Lopes, Renato D. and Merkely, Béla Péter and Parikh, Puja B. and Parkhomenko, Alexander and Ponikowski, Piotr and Rossello, Xavier and Schou, Morten and Simic, Dragan and Steg, P. Gabriel and Szachniewicz, Joanna and van der Meer, Peter and Vinereanu, Dragos and Zieroth, Shelley and Brueckmann, Martina and Sumin, Mikhail and Bhatt, Deepak L. and Hernandez, Adrian F.},
	doi = {10.1056/NEJMoa2314051},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {In press},
	unique-id = {34801043},
	issn = {0028-4793},
	year = {2024},
	eissn = {1533-4406},
	pages = {In press},
	orcid-numbers = {Harrington, Josephine/0000-0001-5169-117X; Gasior, Tomasz/0000-0001-5088-4164; Merkely, Béla Péter/0000-0001-6514-0723; Rossello, Xavier/0000-0001-6783-8463; Steg, P. Gabriel/0000-0001-6896-2941}
}

@article{MTMT:34799254,
	title = {Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction},
	url = {https://m2.mtmt.hu/api/publication/34799254},
	author = {Gibson, C. Michael and Duffy, Danielle and Korjian, Serge and Bahit, M. Cecilia and Chi, Gerald and Alexander, John H. and Lincoff, A. Michael and Heise, Mark and Tricoci, Pierluigi and Deckelbaum, Lawrence I. and Mears, Sojaita Jenny and Nicolau, Jose C. and Lopes, Renato D. and Merkely, Béla Péter and Lewis, Basil S. and Cornel, Jan H. and Trebacz, Jaroslaw and Parkhomenko, Alexander and Libby, Peter and Sacks, Frank M. and Povsic, Thomas J. and Bonaca, Marc and Goodman, Shaun G. and Bhatt, Deepak L. and Tendera, Michal and Steg, P. Gabriel and Ridker, Paul M. and Aylward, Philip and Kastelein, John J. P. and Bode, Christoph and Mahaffey, Kenneth W. and Nicholls, Stephen J. and Pocock, Stuart J. and Mehran, Roxana and Harrington, Robert A.},
	doi = {10.1056/NEJMoa2400969},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	unique-id = {34799254},
	issn = {0028-4793},
	abstract = {Background Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.Methods We conducted an international, double-blind, placebo-controlled trial involving patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors. Patients were randomly assigned to receive either four weekly infusions of 6 g of CSL112 or matching placebo, with the first infusion administered within 5 days after the first medical contact for the acute myocardial infarction. The primary end point was a composite of myocardial infarction, stroke, or death from cardiovascular causes from randomization through 90 days of follow-up.Results A total of 18,219 patients were included in the trial (9112 in the CSL112 group and 9107 in the placebo group). There was no significant difference between the groups in the risk of a primary end-point event at 90 days of follow-up (439 patients [4.8%] in the CSL112 group vs. 472 patients [5.2%] in the placebo group; hazard ratio, 0.93; 95% confidence interval [CI], 0.81 to 1.05; P=0.24), at 180 days of follow-up (622 patients [6.9%] vs. 683 patients [7.6%]; hazard ratio, 0.91; 95% CI, 0.81 to 1.01), or at 365 days of follow-up (885 patients [9.8%] vs. 944 patients [10.5%]; hazard ratio, 0.93; 95% CI, 0.85 to 1.02). The percentage of patients with adverse events was similar in the two groups; a higher number of hypersensitivity events was reported in the CSL112 group.Conclusions Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.) In patients with acute MI, multivessel coronary artery disease, and other cardiovascular risk factors, CSL112 did not reduce the risk of MI, stroke, or death from cardiovascular causes.},
	keywords = {RISK; EFFLUX; Reverse cholesterol transport; CSL112},
	year = {2024},
	eissn = {1533-4406},
	orcid-numbers = {Lincoff, A. Michael/0000-0001-8175-2121; Merkely, Béla Péter/0000-0001-6514-0723}
}

@article{MTMT:34783162,
	title = {Gantenerumab in Early Alzheimer’s Disease},
	url = {https://m2.mtmt.hu/api/publication/34783162},
	author = {Wang, Z. and Zhao, B. and Jia, J.},
	doi = {10.1056/NEJMc2314291},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34783162},
	issn = {0028-4793},
	keywords = {Humans; human; letter; letter; positron emission tomography; Alzheimer disease; Alzheimer disease; Alzheimer disease; amyloid beta protein; tau protein; Antibodies, Monoclonal, Humanized; phase 3 clinical trial (topic); GANTENERUMAB; GANTENERUMAB; amyloid beta protein antibody; donanemab; lecanemab},
	year = {2024},
	eissn = {1533-4406},
	pages = {866}
}

@article{MTMT:34780211,
	title = {Wearable Digital Health Technology for Epilepsy},
	url = {https://m2.mtmt.hu/api/publication/34780211},
	author = {Donner, E. and Devinsky, O. and Friedman, D.},
	doi = {10.1056/NEJMra2301913},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34780211},
	issn = {0028-4793},
	abstract = {This review article presents two true-life clinical vignettes that illustrate how digital health technology can aid providers caring for patients with epilepsy. Specific information that would identify real patients has been removed or altered. The vignettes are followed by a discussion of how these methods were used in the care of the patients. Copyright © 2024 Massachusetts Medical Society.},
	keywords = {Electrocardiography; Humans; EPILEPSY; EPILEPSY; EPILEPSY; review; human; Quality of Life; Sensitivity and Specificity; risk factor; carbamazepine; Electroencephalography; TECHNOLOGY; TECHNOLOGY; Electromyography; Heart Rate; Muscle Contraction; pulse rate; disease activity; intellectual impairment; tonic clonic seizure; adrenergic system; AMNESIA; juvenile myoclonic epilepsy; Accelerometry; brain radiography; digital health; photoelectric plethysmography; Sleep hygiene; vignette; myoclonus seizure; Digital health technology; wearable electronic devices; Convulsive seizure; generalized tonic seizure; non-convulsive epilepsy},
	year = {2024},
	eissn = {1533-4406},
	pages = {736-7445}
}

@article{MTMT:34780911,
	title = {Silencing Immune Dialogue in Multiple Sclerosis},
	url = {https://m2.mtmt.hu/api/publication/34780911},
	author = {Hauser, S.L.},
	doi = {10.1056/NEJMe2314434},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34780911},
	issn = {0028-4793},
	keywords = {Inflammation; Humans; GENETICS; human; MACROPHAGE; editorial; innate immunity; Nerve Degeneration; nuclear magnetic resonance imaging; immune system; placebo; b lymphocyte; tissue injury; immune response; T lymphocyte; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS; gadolinium; microglia; cytokine release; blood brain barrier; gene silencing; antigen presenting cell; CD40 ligand; cytotoxic T lymphocyte antigen 4; frexalimab},
	year = {2024},
	eissn = {1533-4406},
	pages = {662-663}
}

@article{MTMT:34814633,
	title = {Cardiac Implantable Electronic Devices.},
	url = {https://m2.mtmt.hu/api/publication/34814633},
	author = {Al-Khatib, S.M.},
	doi = {10.1056/NEJMra2308353},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34814633},
	issn = {0028-4793},
	keywords = {Humans; review; human; clinical feature; HEART; HEART; heart failure; RADIOTHERAPY; Cardiology; Electronics; Clinical outcome; Pacemaker, Artificial; Defibrillators, Implantable; complete heart block; Electromagnetism; heart muscle conduction system; heart atrium pacing; cardiac resynchronization therapy; heart perforation; heart failure with reduced ejection fraction; heart ventricle pacing; SICK SINUS SYNDROME; Arrhythmias/Pacemakers/Defibrillators; Cardiology General},
	year = {2024},
	eissn = {1533-4406},
	pages = {442-454}
}

@article{MTMT:34768780,
	title = {Adjuvant Alpelisib Therapy for Congenital Hyperinsulinism.},
	url = {https://m2.mtmt.hu/api/publication/34768780},
	author = {Dauleh, H. and Amin, R. and Pasha, M. and Hussain, K.},
	doi = {10.1056/NEJMc2312807},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34768780},
	issn = {0028-4793},
	year = {2024},
	eissn = {1533-4406},
	pages = {379-380}
}

@article{MTMT:34643511,
	title = {Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma},
	url = {https://m2.mtmt.hu/api/publication/34643511},
	author = {Sonneveld, Pieter and Dimopoulos, Meletios A. and Boccadoro, Mario and Quach, Hang and Ho, P. Joy and Beksac, Meral and Hulin, Cyrille and Antonioli, Elisabetta and Leleu, Xavier and Mangiacavalli, Silvia and Perrot, Aurore and Cavo, Michele and Belotti, Angelo and Broijl, Annemiek and Gay, Francesca and Mina, Roberto and Nijhof, Inger S. and van de Donk, Niels W. C. J. and Katodritou, Eirini and Schjesvold, Fredrik and Sureda Balari, Anna and Rosinol, Laura and Delforge, Michel and Roeloffzen, Wilfried and Silzle, Tobias and Vangsted, Annette and Einsele, Hermann and Spencer, Andrew and Hajek, Roman and Jurczyszyn, Artur and Lonergan, Sarah and Ahmadi, Tahamtan and Liu, Yanfang and Wang, Jianping and Vieyra, Diego and van Brummelen, Emilie M. J. and Vanquickelberghe, Veronique and Sitthi-Amorn, Anna and de Boer, Carla J. and Carson, Robin and Rodriguez-Otero, Paula and Blade, Joan and Moreau, Philippe},
	doi = {10.1056/NEJMoa2312054},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {390},
	unique-id = {34643511},
	issn = {0028-4793},
	year = {2024},
	eissn = {1533-4406},
	pages = {301-313},
	orcid-numbers = {Hajek, Roman/0000-0001-6955-6267}
}